- Home
- NEN vs NTHI Comparison
NEN vs NTHI Comparison
Compare NEN & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- NTHI
- Stock Information
- Founded
- NEN 1977
- NTHI 2008
- Country
- NEN United States
- NTHI United States
- Employees
- NEN N/A
- NTHI N/A
- Industry
- NEN Building operators
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- NEN Real Estate
- NTHI Health Care
- Exchange
- NEN Nasdaq
- NTHI Nasdaq
- Market Cap
- NEN 250.0M
- NTHI 211.9M
- IPO Year
- NEN N/A
- NTHI N/A
- Fundamental
- Price
- NEN $71.05
- NTHI $10.35
- Analyst Decision
- NEN
- NTHI
- Analyst Count
- NEN 0
- NTHI 0
- Target Price
- NEN N/A
- NTHI N/A
- AVG Volume (30 Days)
- NEN 824.0
- NTHI 58.8K
- Earning Date
- NEN 01-01-0001
- NTHI 11-19-2025
- Dividend Yield
- NEN 6.76%
- NTHI N/A
- EPS Growth
- NEN 34.86
- NTHI N/A
- EPS
- NEN 4.59
- NTHI N/A
- Revenue
- NEN $83,884,808.00
- NTHI $59,990.00
- Revenue This Year
- NEN N/A
- NTHI N/A
- Revenue Next Year
- NEN N/A
- NTHI N/A
- P/E Ratio
- NEN $15.48
- NTHI N/A
- Revenue Growth
- NEN 4.96
- NTHI N/A
- 52 Week Low
- NEN $68.41
- NTHI $3.20
- 52 Week High
- NEN $84.00
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- NEN 44.84
- NTHI N/A
- Support Level
- NEN $71.05
- NTHI N/A
- Resistance Level
- NEN $73.50
- NTHI N/A
- Average True Range (ATR)
- NEN 0.55
- NTHI 0.00
- MACD
- NEN -0.02
- NTHI 0.00
- Stochastic Oscillator
- NEN 0.00
- NTHI 0.00
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).